CLINICAL MODULATION OF EPIRUBICIN RESISTANCE BY LONIDAMINE IN PATIENTS WITH ADVANCED SOFT-TISSUE SARCOMAS

  • Authors:
    • M LOPEZ
    • S CARPANO
    • L DILAURO
    • L CHIATTI
    • P VICI
    • F CAVALIERE
    • P GENTILE
    • G CITRO
  • View Affiliations

  • Published online on: February 1, 1995     https://doi.org/10.3892/ijo.6.2.363
  • Pages: 363-367
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To determine if lonidamine (LND) could reverse anthracycline resistance In patients with advanced, soft-tissue sarcomas, thirty-six patients were treated with epirubicin (EPI) 120 mg/m(2) i.v. every 3 weeks. Progressive patients were given the same chemotherapy regimen on day 4 in combination with oral LND, 150 mg on day 1, 300 mg on day 2, and 450 mg on days 3 to 5. Among 35 evaluable patients there were 2 complete responses and 3 partial responses (PR) for an overall response rate of 14%. In the group treated with EPI+LND (24 evaluable patients) 2 PR were observed, lasting 3 and 10 months respectively. The overall survivall was 11.5 months. The most common side-effects were myelotoxicity, nausea and vomiting. Clinical cardiotoxicity was. not observed. Only in one patient a >20% decrease in LVEF from baseline was recorded. LND related toxicities were mild to moderate myalgia and photophobia. In a pharmacokinetic study performed parallel to the clinical study, no difference was observed between the parameters derived from EPI and EPI+LND curves except for Vapp. This study indicates that LND may circumvent clinical resistance in some cases without altering chemotherapy related toxicity.

Related Articles

Journal Cover

February 1995
Volume 6 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
LOPEZ, M., CARPANO, S., DILAURO, L., CHIATTI, L., VICI, P., CAVALIERE, F. ... CITRO, G. (1995). CLINICAL MODULATION OF EPIRUBICIN RESISTANCE BY LONIDAMINE IN PATIENTS WITH ADVANCED SOFT-TISSUE SARCOMAS. International Journal of Oncology, 6, 363-367. https://doi.org/10.3892/ijo.6.2.363
MLA
LOPEZ, M., CARPANO, S., DILAURO, L., CHIATTI, L., VICI, P., CAVALIERE, F., GENTILE, P., CITRO, G."CLINICAL MODULATION OF EPIRUBICIN RESISTANCE BY LONIDAMINE IN PATIENTS WITH ADVANCED SOFT-TISSUE SARCOMAS". International Journal of Oncology 6.2 (1995): 363-367.
Chicago
LOPEZ, M., CARPANO, S., DILAURO, L., CHIATTI, L., VICI, P., CAVALIERE, F., GENTILE, P., CITRO, G."CLINICAL MODULATION OF EPIRUBICIN RESISTANCE BY LONIDAMINE IN PATIENTS WITH ADVANCED SOFT-TISSUE SARCOMAS". International Journal of Oncology 6, no. 2 (1995): 363-367. https://doi.org/10.3892/ijo.6.2.363